Scientific knowledge has enabled us to derive
therapy for different disorders. But many diseases still need attention regarding their definitive
treatment plan and oral submucous fibrosis is among those diseases.It is a condition having higher
tendency for malignant transformation(1)
.The habit of areca nut chewing plays a major role in disease
initiation and progression especially to those individuals who have southeast
Chief sites affected are cheek mucousa,faucial pillar and
soft palate. Masticatory muscles and underlying muscles may also get
Various modalities for symptomatic relief have been advocated
but still no definite treatment strategy exists,because fibrosis involved in
this condition can’t be reversed(4).
Initial and extremely important measure to treat it is to
discontinue the habit and it can be done through educating the person regarding
the disease and its consequences,moral support and methods of oral hygiene
Current management options are hyaluronidase injection, intralesional
hydrocortisone, intralesional triamcinolone, extracts from placenta, lycopene ,colchicine
plus vitamin and iron supplements.
Surgery is necessary when extreme
limitation of opening of mouth or biopsy proven dysplastic or neoplastic cells are
derived from methylxanthine and has shown good results in the treatment of
(OSMF) due to it’s discrete effects like modification of physiology of
fibroblasts ,fibrinolysis and anti-inflammatory characteristics
Other actions of Pentoxifylline are peroxide
degranulation and release, increase in natural killer cells(NK) activity,tumor
necrosis factor(TNF) production limitation and provocation of T and B cells.
Ø Hence anti-inflammatory and immune regulating actions of
pentoxifylline may have therapeutic advantages for OSMF management.
The purpose of my study is to evaluate
the efficacy of this relatively newer drug in the management